For the Inventor, By the Inventor

Enter assignee name

Rochester, NY, United States of America

Vaccinex, Inc.

Calculating rank

USPTO Granted Patents = 53

% Expired Patents = 11.3

CIPO Patents = 7

EPO Patents = 24

Trademarks = 1

Forward Citations = 373

Loading Chart...

Loading Chart...

40 inventors (with patents filed for the assignee):

Ernest S Smith (44 out of 47 patents)

Maurice Zauderer (28 out of 41 patents)

Mark Paris (13 out of 13 patents)

4. Elizabeth E Evans (11 out of 19 patents)

5. Terrence Lee Fisher (9 out of 19 patents)

6. Renee A Kirk (8 out of 8 patents)

7. Angelica A Cornelison (7 out of 7 patents)

8. Maria G M Scrivens (6 out of 6 patents)

9. William J Bowers (4 out of 9 patents)

10. Alan Jonason (4 out of 4 patents)

11. Leslie A Balch (4 out of 4 patents)

12. Leslie A Croy (4 out of 4 patents)

13. Maria Scrivens (4 out of 4 patents)

14. Ekaterina Klimatcheva (3 out of 3 patents)

15. Tracy Pandina (3 out of 3 patents)

Core Competencies:

Anti-CD100

Anti-CCR8

Anti-CXCL13

Semaphorin-4D

Neurodegenerative Disorders

Tumor Growth

Immunomodulating Therapy

Antibody Combination Therapy

Viral Protein Display

Polynucleotides

Cancer Treatment

Epigenetic Modulation

53 patents: Sort by Forward Citations

1. 12668630 - HUMAN ANTI-SEMAPHORIN 4D ANTIBODY (2026-06-30),

2. 12496342 - Anti-CCR8 Antibodies and Uses Thereof (2025-12-16),

3. 12201719 - Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy (2025-01-21),

4. 12070500 - Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis (2024-08-27),

5. 12006365 - Human anti-semaphorin 4D antibody (2024-06-11),

6. 12006364 - Anti-CD100 antibodies and methods for using the same (2024-06-11),

7. 11981730 - Anti-CXCL13 antibodies and methods of using the same (2024-05-14),

8. 11976383 - Integral membrane protein display on poxvirus extracellular enveloped virions (2024-05-07),

9. 11859000 - Anti-CCR8 antibodies and uses thereof (2024-01-02),

10. 11660330 - Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy (2023-05-30),

11. 11597765 - Use of semaphorin-4D binding molecules for the treatment of Rett syndrome (2023-03-07),

12. 11572408 - Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent (2023-02-07),

13. 11534488 - Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability (2022-12-27),

14. 11427634 - Human anti-semaphorin 4D antibody (2022-08-30),

15. 11274149 - Anti-CD100 antibodies and methods for using the same (2022-03-15),

Company Overview

Vaccinex, Inc., based in Rochester, NY, specializes in the development of innovative antibody therapeutics aimed at addressing serious medical conditions. The company focuses on advancing treatments for neurodegenerative disorders and tumor growth through its proprietary technologies, including anti-CD100, anti-CCR8, anti-CXCL13, and semaphorin-4D. Vaccinex is dedicated to exploring immunomodulating and antibody combination therapies to enhance patient outcomes in challenging therapeutic areas.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

53 Patents

#20 in Rochester, NY

#408 in New York

#6,674 in US

#13,356 in the World

Rochester, NY, United States of America

Vaccinex, Inc.

Forward Citations = 373

40 inventors:

Ernest S Smith (44 out of 47 patents)

Maurice Zauderer (28 out of 41 patents)

Mark Paris (13 out of 13 patents)

4. Elizabeth E Evans (11 out of 19 patents)

5. Terrence Lee Fisher (9 out of 19 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Vaccinex, Inc.. Retrieved from https://idiyas.com/company/vaccinex

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…